Clinical trial · Interventional
Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication
Evaluating Adherence and Persistence in Patients Receiving Oral Oncolytic Therapy in a Safety Net Hospital's Pharmacist-driven Medication Management Program
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Boston Medical Center provides care to cancer patients on oral cancer medications through the use of Boston Medical Center Specialty Pharmacy (BMC SP). The use of oral medications in cancer treatments is relatively new and unfortunately, very little is known about adherence in cancer patients. This study will evaluate the influence of a pharmacist-driven medication management program on adherence and persistence rates. Boston Medical Center's Specialty Pharmacy Adherence Program (B-SPAP), will utilize a high-touch counseling model involving clinical pharmacist that will focus on educating patients about their oral cancer treatments. The program will require face-to-face counseling with a pharmacist, through the use of a proven patient teaching tool, prior to initiating treatment with oral oncolytic treatments and, periodically thereafter, based on protocol. This study will help improve our understanding of the role of the pharmacist in cancer patients. In addition, the study will help identify independent factors that may contribute or impact adherence. The outcomes of this program will be compared to a historical control group of patients that have already received treatment for their cancer through the BMC Specialty Pharmacy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adherence, Medication | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Historical control | Behavioral | — | UNRESOLVED |
| pharmacist-intervention | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Historical Control
- description
- Pharmacy care was standard, high-touch model where an institutional specialty pharmacy contact patients via telephone. Standard adherence and counseling was offered over the phone to patients.
- interventionNames
- Behavioral: Historical control
- type
- EXPERIMENTAL
- label
- Pharmacist-intervention
- description
- In-person counseling with a clinical pharmacist prior and during treatment with an oral oncology medication. Patients meet with a clinical pharmacist prior, at month 3 and month 6 during the study.
- interventionNames
- Behavioral: pharmacist-intervention
Primary outcomes (2)
- measure
- Medication Possession Ratio
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Pharmacist-intervention group Inclusion Criteria: 1. Treatment with 1 or more oral oncology agents. Oral oncology agent defined as medication taken mouth with the purpose to treat a patient's cancer 2. Treatment dispensed through the BMC Specialty Pharmacy 3. Age\>18 years 4. Life expectancy \>6 months 5. Patients must have ability to give written consent, or, must have a legally authorized representative Exclusion Criteria: 1. Treatment indicated for neoadjuvant, adjuvant, peri-operative treatment 2. Concurrent radiation treatment 3. Patients that are unable to have oral oncology agents dispense through BMC Specialty Pharmacy Historical Control: 1. 2 controls:1 intervention match 2. Matched to a patient in intervention group based on drug type
References
Publications (0)
Data not yet available